Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.
Giulia BegaJacopo OlivieriMarcello RivaGreta ScapinelloRossella PaoliniSilvia FinottoRoberto SartoriElisa LucchiniGianmarco GuandaliniDavide FacchinelliMaria Chiara TisiMarco BassoLaura BallottaFrancesco A PiazzaIsacco FerrariniChiara RusconiPublished in: Cancers (2021)
This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.